Verifying the accuracy of the dose calculation algorithm is considered one of the most critical steps in radiotherapy treatment for delivering an accurate dose to the patient. This work aimed to evaluate the dosimetric performance of the treatment planning system (TPS) algorithms; the AAA (v. 15.6), AXB (v. 15.6) and eMC (v. 15.6) following the AAPM medical physics practice guideline 5.a (MPPG 5.a) validation tests package in a Varian iX Linear Accelerator (Linac). A series of tests were developed based on the MPPG 5.a. on a Varian's Eclipse TPS (v. 15.6) (Varian Medical Systems). First, the basic photon and electron tests were validated by comparing the TPS calculated dose with the measurements. Next, for heterogeneity tests, we verified the Computed Tomography number to electron density (CT-to-ED) curve by comparing it with the baseline values, and TPS calculated point doses beyond heterogeneous media were compared to the measurements. Finally, for IMRT/VMAT dose validation tests, clinical reference plans were re-calculated on ArcCheck's virtual phantom (Sun Nuclear Corporation, Melbourne, FL, USA) and exported to the Linac for delivery using the ArcCheck dosimetry system. All validation tests were evaluated following the MPPG 5.a recommended tolerances. In basic dose validation tests, the TPS calculated depth dose profiles agreed well with the measurements, with a minimum gamma passing rate of 95% at 2%/2 mm criteria. However, disagreements are seen in the build-up and penumbra region. Results for most point doses in homogeneous water phantoms were within the MPPG 5.a tolerance. For the heterogeneity tests, the CT-to-ED curve was established, and calculated point doses were all within 3% of the measurements for heterogeneous media for both photon algorithms at three energies. These results are within the MPPG5.a the recommended tolerance of 3%. Moreover, for electron beams, the differences between the calculated and measured point doses averaged 5% and 7%, but were just within the MPPG 5.a tolerance of 7%. For IMRT and VMAT validation tests using a gamma criteria of a 2%/2 mm, IMRT plans showed maximum and minimum passing rates of 98.2% and 97.4%, respectively. Whereas VMAT plans showed maximum and minimum passing rates of 100% and 94.3%, respectively. We conclude that the dosimetric accuracy of the Eclipse TPS (v15.6) algorithm is adequate for clinical use. The MPPG 5.a tests are valuable for evaluating dose calculation accuracy and are very useful for TPS upgrade checks, commissioning tests, and routine TPS QA.

验证剂量计算算法的准确性被认为是放射治疗中向患者提供准确剂量的最关键步骤之一。这项工作旨在评估治疗计划系统 (TPS) 算法的剂量学性能；AAA (v. 15.6)、AXB (v. 15.6) 和 eMC (v. 15.6) 遵循 Varian iX 线性加速器 (Linac) 中的 AAPM 医学物理实践指南 5.a (MPPG 5.a) 验证测试包。基于 MPPG 5.a 开发了一系列测试。在 Varian 的 Eclipse TPS (v. 15.6) (Varian Medical Systems) 上。首先，通过将 TPS 计算的剂量与测量值进行比较，验证了基本的光子和电子测试。接下来，对于异质性检验，我们通过将其与基线值进行比较来验证计算机断层扫描数字与电子密度 (CT-to-ED) 曲线，并将 TPS 计算的超出异质介质的点剂量与测量值进行比较。最后，对于 IMRT/VMAT 剂量验证测试，临床参考计划在 ArcCheck 的虚拟模型（Sun Nuclear Corporation，Melbourne，FL，USA）上重新计算，并使用 ArcCheck 剂量测定系统导出到 Linac 以进行交付。所有验证测试均按照 MPPG 5.a 推荐的公差进行评估。在基本剂量验证测试中，TPS 计算的深度剂量分布与测量值非常吻合，在 2%/2 mm 标准下的最低伽马通过率为 95%。然而，在建筑和半影区域存在分歧。均质水模型中大多数点剂量的结果都在 MPPG 5.a 公差范围内。对于异质性测试，建立了 CT 到 ED 曲线，计算出的点剂量在三种能量下两种光子算法的异质介质测量值的误差都在 3% 以内。这些结果在 MPPG5.a 推荐的 3% 公差范围内。此外，对于电子束，计算点剂量与测量点剂量之间的差异平均为 5% 和 7%，但恰好在 MPPG 5.a 7% 的公差范围内。对于使用 2%/2 mm 伽玛标准的 IMRT 和 VMAT 验证测试，IMRT 计划显示的最大和最小通过率分别为 98.2% 和 97.4%。而 VMAT 计划显示的最高和最低通过率分别为 100% 和 94.3%。我们得出结论，Eclipse TPS (v15.1) 的剂量学准确性 6）算法适合临床使用。MPPG 5.a 测试对于评估剂量计算准确性很有价值，并且对于 TPS 升级检查、调试测试和常规 TPS QA 非常有用。